The antiprotozoal compound 1,5-di(4-amidinophenoxy)pentane (pentamidine) and 36 of its analogs were screened for in vitro activity against Leishmania mexicana amazonensis clone 669 C4S (MHOM/BR/73/M2269) and Plasmodium falciparum clones W2 (Indochina HI/CDC) and D6 (Sierra Leone I/CDC). Pentamidine and each of the analogs tested exhibited activity in vitro against L. m. amazonensis and P. falciparum. The pentamidine analogs were more effective against the P. falciparum clones than against L. m. amazonensis. P. falciparum was extremely susceptible to these compounds, with 50% inhibitory concentrations as low as 0.03 FpM. While none of the analogs exhibited marked improvement in antileishmanial activity compared with pentamidine, 12 of the pentamidine analogs showed activity approximately equal to or greater than that of the parent compound. From the promising activity exhibited by the pentamidine analogs in this in vitro study and their potential for reduced toxicity relative to the parent drug, pentamidine-related compounds hold promise as new agents for the treatment of protozoal infections.
The efficacy of aromatic diamidines in the treatment of protozoal diseases was first recognized in the 1930s by investigators searching for agents with therapeutic activity against African trypanosomiasis (14) . Early clinical trials examining the activities of pentamidine, propamidine, and stilbamidine revealed that these and other aromatic diamidines are effective against the early stages of African trypanosomiasis (6, 7, 13, 14) and against leishmaniasis (11, 15, 22) . Although they are not clinically used in the treatment of malaria, the antiplasmodial activity of aromatic diamidines in monkeys infected with Plasmodium knowlesi was demonstrated during the 1940s (1, 4) .
Aromatic diamidines not only have antiprotozoal activity but also exhibit activity against bacteria (3), fungi (3), viruses (21) , and tumors (12) . In the past, their use has mainly been confined to the treatment of protozoal diseases, for which they were first developed. Pentamidine continues to be used in the treatment of the Gambian form of African trypanosomiasis and against antimony-resistant leishmaniasis (17) . Pentamidine was first shown to be active against the opportunistic pathogen Pneumocystis carinii in 1958 (10) , and in the United States, this compound is primarily used to treat P. carinii pneumonia in patients with the acquired immune deficiency syndrome. The toxicity and side effects associated with the use of pentamidine in the treatment of P. carinii pneumonia in acquired immune deficiency syndrome patients have led to extensive investigations to identify a derivative of pentamidine which is more active against P. carinii pneumonia and less toxic than the parent drug.
To this end, over 50 analogs of pentamidine have been synthesized in our laboratory and have been examined for in vivo efficacy against P. carinii in the rat model of disease (10a, 18, 19) . The design of more-potent analogs of pentamidine against P. carinii pneumonia has been hampered by the lack of a reliable in vitro culture system for this organism. In an effort to better understand the mechanism of antiparasitic * Corresponding author. activity of pentamidine analogs and to determine the range of their antiprotozoal effect, we have examined the structureactivity relationships of pentamidine analogs in vitro against Leishmania mexicana amazonensis clone 669 C4S (MHOM/ BR/73/M2269) and two clones of Plasmodium falciparum, W2 (Indochina III/CDC), which is resistant to chloroquine and susceptible to mefloquine, and D6 (Sierra Leone I/ CDC), which is susceptible to chloroquine and resistant to mefloquine.
MATERIALS AND METHODS
Chemotherapeutic agents. Pentamidine and the analogs of pentamidine used in this study were synthesized as mono-or dihydrochloride salts in the laboratories of Richard R. Tidwell, Department of Pathology, School of Medicine, University of North Carolina at Chapel Hill. The syntheses of these compounds were carried out by methods which have been previously described (18, 19) . High-performance liquid chromatography, elemental analyses, and proton magnetic resonance were used to determine the purity of the compounds.
Cultivation of parasites. Two clones of P. falciparum were used in these studies, W2 (Indochina III/CDC) and D6 (Sierra Leone I/CDC) (16) . These parasite clones were maintained in vitro by modifications of previously described methods (8, 16, 20) . Briefly, the clones were maintained in 5-ml suspensions of human type A-positive (A+) erythrocytes at a parasitemia of 0.2 to 0.4% and a hematocrit of 6% in RPMI 1640 culture medium with 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), 25 mM NaHCO3, and 10% human plasma. The replacing the amidino groups with imidazolino moieties although the IC5o of the most active meta-amidinophenoxy (Table 6 ). The amidinoanilino and imidazolino compounds compound, the six-carbon analog (compound 8), was more were further varied by placing substituents upon their arothan twice as high as that of the corresponding six-carbon matic rings (Tables 5 and 6 , respectively).
para-amidinophenoxy compound (compound 4). Antileishmanial activity. Table 1 contains antileishmanial The effect of placing various substituents ortho to the data from compounds in which the length of the alkyl bridge ether bridge on both aromatic rings of the para-amidinophewas varied from two to six carbons. Each of these derivanoxy compounds is shown in Table 3 . Substitution of nitro tives exhibited activity against L. m. amazonensis, with (compounds 9 to 11), amino (compounds 12 to 14) or pentamidine having an IC50 of 0.820 ± 0.019 ,uM (mean + methoxy (compounds 15 to 17) groups on the aromatic rings standard error). The six-carbon analog, hexamidine (comresulted in all cases in decreased antileishmanial activity pound 4), was approximately twofold more active than relative to the unsubstituted 4-amidinophenoxy compounds pentamidine, and the three-carbon compound, propamidine (Table 1) . Chloro (compounds 18 and 19) and bromo (com-(compound 2), exhibited activity approximately equal to that pound 20) substitution, however, slightly increased or did of pentamidine. The two-and four-carbon analogs (comnot greatly alter antileishmanial activity, with IC50s of 0.703 pounds 1 and 3) showed decreased activity compared with + 0.101 ,uM and 0.677 ± 0.016 ,uM, respectively, for the that of pentamidine.
chloro-substituted (compound 19) and bromo-substituted Moving the amidino groups from para to meta positions (compound 20) derivatives of pentamidine. resulted in decreased antileishmanial activity (Table 2) comIsosteric replacement of ether oxygens with nitrogens pared with that observed for the corresponding para-amidi- (Table 4 ) produced analogs (compounds 21 to 24) with equal nophenoxy compounds (Table 1 ). Increasing the chain or improved activity against L. m. amazonensis in comparlength of the alkyl bridge of the meta-amidinophenoxy ison with the corresponding 4-amidinophenoxy compounds compounds increased their activity against clone 669 C4S, ( Table 1) . As was the case with the meta-amidinophenoxy compounds, activity in this series increased with increasing rings meta to the imidazolino moiety produced compounds alkyl-chain length. The six-carbon 4-amidinoanilino com-(compounds 34 to 36) with decreased activities relative to pound (compound 24) was one of the most active antileishthose of the unsubstituted 4-imidazolinophenoxy commanial compounds tested in this study, with an IC50 of 0.289 pounds (compounds 31 to 33), and similar or decreased + 0.055 ,uM, slightly lower than that of the corresponding activities relative to those of the methoxy-substituted 4-
4-amidinophenoxy compound (compound 4). The three-, amidinophenoxy analogs (compounds 15 to 17). four-, and five-carbon 4-amidinoanilino compounds (com-
Antiplasmodial activity. 4-Amidinophenoxy compounds pounds 21 to 23) also exhibited high antileishmanial activity with alkyl bridges ranging from two to six carbons exhibited with IC50s slightly lower than or similar to those of the relatively high antiplasmodial activities, although the activcorresponding 4-amidinophenoxy compounds.
ities against the two clones of P. falciparum were different The in vitro activities of nitro-and amino-substituted ( Table 1) . Each of the unsubstituted 4-amidinophenoxy 4-amidinoanilino derivatives were also evaluated (Table 5) .
compounds was approximately twice as active against D6 as Nitro (compounds 25 and 26) and amino (compounds 27 to against W2. Of this series, the three-carbon compound, 4-amidinophenoxy compounds (Table 3) .
Moving the amidino groups from para to meta positions Activities of compounds in which the amidino groups were (Table 2 ) resulted in compounds with similar activities replaced with imidazolino moieties are presented in Table 6 Table 3 . In general, the placement of substitution groups on the aromatic rings resulted in approximately equal or decreased activity against P. falciparum relative to that of the unsubstituted 4-amidinophenoxy compounds ( Table 1) .
Replacement of the ether oxygens with nitrogens produced compounds with approximately equal or increased antiplasmodial activities (Table 4) (Table 5) were less active against the P. falciparum clones than were the corresponding unsubstituted 4-amidinoanilino compounds ( Table 4 ). The substituted 4-amidinoanilino compounds had activities approximately equal to those of the corresponding substituted 4-amidinophenoxy compounds (Table 3) .
Compounds in which the amidino groups were replaced with an imidazolino moiety were also examined for in vitro activity against P. falciparum ( (11, 15, 22) , and pentamidine is currently used in the treatment of antimony-resistant leishmaniasis (17) . Thus, the identification of a more potent and/or less toxic derivative of pentamidine might have clinical applications in the treatment of leishmaniasis. Twelve pentamidine analogs examined in this study exhibited antileishmanial activity approximately equal to or higher than that of pentamidine. These include the unsubstituted 4-amidinophenoxy alkanes, propamidine (compound 2) and hexamidine (compound 4), and the unsubstituted six-carbon-chain 3-amidinophenoxy compound (compound 8). The chloro-substituted (compound 19) and bromo-substituted (compound 20) derivatives of pentamidine were similar in activity to pentamidine or were slightly more potent, as were the 4-amidinoanilino alkanes (compounds 21 through 24). Three of the substituted 4-amidinoanilino compounds (compounds 26, 29, and 30) exhibited antileishmanial activity approximately equal to that of pentamidine.
The P. falciparum clones W2 and D6 were in general very susceptible to pentamidine and the derivaties of pentamidine screened in this study. Aromatic diamidines have not been clinically used in the treatment of malaria, but previous in vivo studies (1, 4) and the current in vitro data suggest that further investigation is warranted. Several compounds examined in this study deserve further examination because of their in vitro activity against P. falciparum and their low in vivo toxicity, as observed in rat P. carinii pneumonia studies (lOa, 15, 18) . The three-carbon-chain 4-amidinophenoxy (compound 2) and the three-and five-carbon-chain 4-amidinoanilino compounds (compounds 21 and 23) as well as 3ome of the substituted 4-amidinophenoxy (Table 3 ) and 4-amidinoanilino (Table 5 ) compounds were quite active against both W2 and D6. Likewise, the three-and five-carbon-chain unsubstituted 4-imidazolinophenoxy compounds (compounds 31 and 33) were also quite potent against both clones. One compound which had excellent activity against P. falciparum clone W2, 1,3-di(4-imidazolino-2-methoxyphenoxy)propane (compound 34), had previously demonstrated 10 times the activity of pentamidine against P. carinii pneumonia in the rat model of disease (lOa). This compound was also found to be active against P. carinii pneumonia upon oral administration (lOa). The meta-amidinophenoxy compounds (compounds 5 to 8) exhibited approximately equal activity against both clones ofP. falciparum. The similarities in response by both the chloroquine-resistant and mefloquine-susceptible clone W2 and the chloroquine-susceptible and mefloquine-resistant clone D6 to the meta-amnidinophenoxy compounds warrant further investigation and might also provide a tool with which to examine the mechanism(s) of drug resistance in P. falciparum.
This study has yielded no additional data to assist in determining the mechanism(s) by which pentamidine and its analogs exert antimicrobial activity. However, while amidinophenoxy compounds are effective inhibitors of trypsin, imidazolino compoune s have been found to be devoid of antitrypsin activity and yet are active against P. falciparum and L. m. amazonensis in vitro and P. carinii pneumonia in vivo (18) . Thus, it is unlikely that the antiprotease activity of these compounds is related to their antiprotozoal activity.
Previous work has also revealed that all of the molecules bind to calf thymus DNA, as measured by a thermal denaturation assay (18) . It has also been possible to demonstrate correlations between antiprotozoal activity and DNA binding (unpublished data).
VOL. 34, 1990 on June 20, 2017 by guest http://aac.asm.org/ Downloaded from A better understanding of the mechanism(s) by which these compounds act would greatly aid in the design of more-effective antiprotozoal agents. The continuing emergence of drug-resistant parasites makes the development of additional antiprotozoal drugs of vital importance. The data presented in this study indicate that L. m. amazonensis and P. falciparum are susceptible to these aromatic diamidines and di-imidazolines. This study has identified several compounds with promising antileishmanial and antiplasmodial activities that are worthy of further in vitro and in vivo studies to assess their therapeutic potential. The antimalarial and antileishmanial activities of aromatic diamidines and di-imidazolines, coupled with their potential for reduced toxicity relative to pentamidine, suggest that they hold promise for the treatment of these and other infections.
